Connect with us
European Gaming Congress 2024

Fintech PR

GYMetaverse Invests HKD 100 Million to Revolutionize Health Management Platform – Live4Well with NFT Membership and Sweat and Earn Incentives

Published

on

gymetaverse-invests-hkd-100-million-to-revolutionize-health-management-platform-–-live4well-with-nft-membership-and-sweat-and-earn-incentives

HONG KONG, Sept. 4, 2023 /PRNewswire/ — GYMetaverse, a Web3.0 wellness company headquartered in Hong Kong, announces a ground-breaking HKD 100 million investment to expand its innovative web3 health management platform, Live4Well. Utilizing cutting-edge blockchain technology, Live4Well offers users secure, decentralized, traceable, and controllable self-health management services. With the introduction of VIV Pass (NFT membership), users gain exclusive access to over 200 premier fitness centers across Hong Kong, while exciting Sweat and Earn incentives motivate individuals to achieve their fitness goals like never before.

With this substantial investment, GYMetaverse aims to redefine the landscape of health management, empowering individuals to take control of their well-being through a seamless digital experience.

Unlock a World of Fitness with the VIV Pass: Seamless Access to Premier Gyms Across Hong Kong

The platform will launch an NFT membership pass, “VIV Pass,” and its accompanying mobile application in October. By leveraging the power of NFT membership, users can unlock a network of top-notch gym facilities, spanning all corners of Hong Kong. Moreover, the Sweat and Earn incentives provide a unique opportunity for users to earn rewards and benefits by simply engaging in their fitness routines. Its features include:

  • ANYWHERE: Users can enjoy seamless access to a network of over 200 fitness centers across Hong Kong using the VIV Pass through Live4Well’s partnership. Participating fitness centers are located in all 18 districts of Hong Kong, including popular establishments such as Anytime Fitness, 24/7 Fitness, FIT24 Hong Kong, EMS Fitness Hong Kong, Inspire Yoga, and many more.
  • ANYTIME: The mobile application combines artificial intelligence (AI) and motion capture technology to accurately measure human body movements, assisting users in improving their exercise posture. Users can engage in physical training anytime, anywhere, as if they have a 24/7 personal fitness coach by their side.
  • Sweat and Earn: Users can also earn digital currency, Sweat Coins, through exercise, achieving the concept of “Sweat and Earn.” Sweat Coins can be used to redeem rewards, participate in sports courses and professional lectures, and even exchange for the digital token (L4W), allowing users to explore the world of Web3 ecosystem through real-world applications.

The Era of “Health 3.0: Live4Well and GYMetaverse’s Vision for a Holistic Approach to Health”
GYMetaverse’s Live4Well platform is revolutionizing the concept of health with its innovative approach known as “Health 3.0.” The healthcare landscape has transitioned from the directive Health 1.0, where companies and health organizations provided wellness instructions, to the interactive Health 2.0, offering personalized consultations. We’re now entering the era of Health 3.0, the future of wellness where users drive their health choices. In this new stage, individuals are not just recipients but active participants, empowered with the freedom to shape their health journeys. Through this shift, healthcare becomes a more personalized and effective experience.

From Sportswear to Health Management: GYMetaverse’s Evolution and the Live4Well Platform
Established in 2022, GYMetaverse has come a long way since its inception. In 2017, the investors of the company completed a 100% acquisition of the renowned German sports brand Gym Aesthetics (GA). This significant move expanded their ambitions beyond sportswear sales. Venturing into the sports and technology industries, Gym Aesthetics made strategic investments in projects under Animoca Brands and formed collaborations with key stakeholders in the sports world. Notable partnerships included working with Alain Ngalani, a four-time Muay Thai world champion, and Sergi Constance, a Spanish fitness model with over 6 million followers on Instagram.

Advertisement
Stake.com

Over the past six years, Gym Aesthetics has worked closely with more than 100 fitness coaches to organize successful online and offline fitness events, solidifying its expertise and fostering a vibrant community of fitness enthusiasts. Now, GYMetaverse is poised to embark on an exciting new chapter, leveraging on its resources to create a user-driven health management platform infused with web3 elements.

To realize this transformative vision, GYMetaverse has committed a substantial investment of HKD 100 million into the development of the Live4Well platform. This dedicated investment underscores the company’s unwavering commitment to creating a flagship web3 project that revolutionizes health management for the people of Hong Kong. By leveraging its extensive industry experience and strategic collaborations, GYMetaverse is poised to reshape the future of health and fitness, establishing a transformative ecosystem that empowers individuals to thrive in the era of “Health 3.0.”

https://www.youtube.com/watch?v=aBCY1kOHaT4

About Live4Well
Live4Well is a Web3.0 health management platform that integrates virtual reality to inject a new economic model into the fitness industry. Users can earn Sweat Coins through high-precision exercise on the platform, which can be redeemed for physical gifts, fitness courses, or even digital currency (L4W).

The platform also offers a VIV PASS, which serves as both a pass for accessing multiple gyms and studios across 18 districts in Hong Kong and a tool for measuring users’ body movements to improve their exercise posture. The VIV PASS comes with a mobile app that combines blockchain technology, artificial intelligence, and motion capture technology, providing users with a 24-hour fitness coach. Users need to calculate their sweat capacity in exchange for more rewards and benefits, enjoy the freedom to work out regardless of location.

Advertisement
Stake.com

For further information, please check our website:
https://www.live4well.io

 

Photo – https://mma.prnewswire.com/media/2200463/Live4Well_banner_16_9.jpg

Logo – https://mma.prnewswire.com/media/2200465/Logo_Live4well_final_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/gymetaverse-invests-hkd-100-million-to-revolutionize-health-management-platform—live4well-with-nft-membership-and-sweat-and-earn-incentives-301916579.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

Advertisement
Stake.com

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

Advertisement
Stake.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

Advertisement
Stake.com

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Advertisement
Stake.com

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

Advertisement
Stake.com

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Advertisement
Stake.com
Continue Reading

Trending